Limits...
Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M - Eur. Respir. J. (2014)

Bottom Line: Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa.Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide.Median treatment success was 53% (interquartile range 40-70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010.

View Article: PubMed Central - PubMed

Affiliation: Global TB Programme, World Health Organization, Geneva, Switzerland falzond@who.int.

No MeSH data available.


Related in: MedlinePlus

Multidrug-resistant tuberculosis (MDR-TB) notifications and percentage of funding received for second-line drugs from external sources, by income group, 2012. a) high-income group; b) upper middle-income group; c) lower middle-income group; d) low-income group. Only countries that reported data for both domestic and external funding are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318660&req=5

Figure 4: Multidrug-resistant tuberculosis (MDR-TB) notifications and percentage of funding received for second-line drugs from external sources, by income group, 2012. a) high-income group; b) upper middle-income group; c) lower middle-income group; d) low-income group. Only countries that reported data for both domestic and external funding are shown.

Mentions: Expenditure data for second-line drugs were provided by 12 countries, accounting for 58% of the estimated MDR-TB cases in the 30 countries; in addition, Thailand reported data for the Bangkok metropolitan administration alone (fig. 4). The total funding received by the programmes and spent on these drugs amounted to US$192 million in 2012; 27% of this funding was from external sources. The proportion of external funding had no clear association with the number of MDR-TB cases notified by these countries. The share of external funding was inversely associated with gross national income per capita, adjusted for purchasing power parity until ∼US$5000 per capita (fig. S4 of the online supplementary material). In the Russian Federation (the only high-income country in the group that reported expenditure data), spending on second-line drugs originated wholly from domestic sources. In contrast, in the two low and five lower middle-income countries, second-line drugs were entirely supported by external grants. In upper middle-income countries, the proportion of funding received for second-line drugs from external sources varied, and was >50% in Belarus and China.


Multidrug-resistant tuberculosis around the world: what progress has been made?

Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M - Eur. Respir. J. (2014)

Multidrug-resistant tuberculosis (MDR-TB) notifications and percentage of funding received for second-line drugs from external sources, by income group, 2012. a) high-income group; b) upper middle-income group; c) lower middle-income group; d) low-income group. Only countries that reported data for both domestic and external funding are shown.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318660&req=5

Figure 4: Multidrug-resistant tuberculosis (MDR-TB) notifications and percentage of funding received for second-line drugs from external sources, by income group, 2012. a) high-income group; b) upper middle-income group; c) lower middle-income group; d) low-income group. Only countries that reported data for both domestic and external funding are shown.
Mentions: Expenditure data for second-line drugs were provided by 12 countries, accounting for 58% of the estimated MDR-TB cases in the 30 countries; in addition, Thailand reported data for the Bangkok metropolitan administration alone (fig. 4). The total funding received by the programmes and spent on these drugs amounted to US$192 million in 2012; 27% of this funding was from external sources. The proportion of external funding had no clear association with the number of MDR-TB cases notified by these countries. The share of external funding was inversely associated with gross national income per capita, adjusted for purchasing power parity until ∼US$5000 per capita (fig. S4 of the online supplementary material). In the Russian Federation (the only high-income country in the group that reported expenditure data), spending on second-line drugs originated wholly from domestic sources. In contrast, in the two low and five lower middle-income countries, second-line drugs were entirely supported by external grants. In upper middle-income countries, the proportion of funding received for second-line drugs from external sources varied, and was >50% in Belarus and China.

Bottom Line: Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa.Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide.Median treatment success was 53% (interquartile range 40-70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010.

View Article: PubMed Central - PubMed

Affiliation: Global TB Programme, World Health Organization, Geneva, Switzerland falzond@who.int.

No MeSH data available.


Related in: MedlinePlus